This guidance is another new drug for the use in AF as an anticoagulant. It is a Factor Xa inhibitor and is more effective than warfarin. It hasn’t been shown to be more effective than Rivaroxaban and Dabigatran. It has the lowest bleeding risk. As always, we should wait for local prescribing advice before using.
It can be considered if the patient has non-valvular AF and at least 1 of:
- Prior stroke or TIA
- 75 or older
- Hypertension
- Diabetes
- Symptomatic heart failure